The hazard ratio as a measure of effect in clinical trials of elderly populations: common pitfalls and misconceptions

被引：0
|
作者：
Stefanos Roumeliotis
Graziella D’Arrigo
Giovanni Tripepi
机构：
[1] Aristotle University of Thessaloniki,Division of Nephrology and Hypertension, 1st Department of Internal Medicine, AHEPA Hospital, School of Medicine
[2] Clinical Epidemiology and Physiopathology of Renal Diseases and Hypertension,Institute of Clinical Physiology (IFC
[3] Ospedali Riuniti,CNR)
来源：
Aging Clinical and Experimental Research | 2021年 / 33卷
关键词：
Hazard ratio; Clinical trials; Risk ratio; Elderly;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The hazard ratio is a measure of effect which is of paramount importance in etiological research, that is in studies aimed at assessing the strength of the causal relationship between a given treatment/exposure and a certain outcome. Despite the widespread use of the hazard ratio as a measure of effect in scientific reports and articles, the interpretation of this index is often accompanied by some misconceptions which can jeopardize the critical appraisal of randomized clinical trials (RCTs) and observational studies as well. Herein, using a series of examples derived from RCTs in the elderly subjects, we address major pitfalls regarding the interpretation of the hazard ratio in geriatric research.
引用
收藏
页码：505 / 511
页数：6
相关论文
共 47 条
  • [1] The hazard ratio as a measure of effect in clinical trials of elderly populations: common pitfalls and misconceptions
    Roumeliotis, Stefanos
    D'Arrigo, Graziella
    Tripepi, Giovanni
    AGING CLINICAL AND EXPERIMENTAL RESEARCH, 2021, 33 (03) : 505 - 511
  • [2] Limitations of the Hazard Ratio as a Summary Measure in Cancer Clinical Trials
    Dao, Quynh-Lan
    Phung, Quan
    Liu, Michael A.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : E86 - E87
  • [3] Response to "Limitations of the Hazard Ratio as a Summary Measure in Cancer Clinical Trials"
    Zhao, Hongyun
    Li, Jibin
    Zhang, Zhonghan
    Zhang, Li
    Zhou, Xianfeng
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : E87 - E88
  • [4] Hazard ratio in clinical trials
    Spruance, SL
    Reid, JE
    Grace, M
    Samore, M
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (08) : 2787 - 2792
  • [5] Hazard ratio for recurrent relapses - A modern efficacy measure for clinical trials in relapsing multiple sclerosis
    Bogumil, T
    Jakobs, P
    Salazar-Grueso, E
    Fleming, T
    NEUROLOGY, 2005, 64 (06) : A324 - A324
  • [6] Common pitfalls of RECIST 1.1 application in clinical trials
    Teslenko, I.
    Belotserkovsky, M.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S132 - S132
  • [7] On Confidence Intervals for the Hazard Ratio in Randomized Clinical Trials
    Lin, Dan-Yu
    Dai, Luyan
    Cheng, Gang
    Sailer, Martin Oliver
    BIOMETRICS, 2016, 72 (04) : 1098 - 1102
  • [8] Causal interpretation of the hazard ratio in randomized clinical trials
    Fay, Michael P.
    Li, Fan
    CLINICAL TRIALS, 2024, 21 (05) : 623 - 635
  • [9] Cumulative Hazard Ratio Estimation for Treatment Regimes in Sequentially Randomized Clinical Trials
    Tang X.
    Wahed A.S.
    Statistics in Biosciences, 2015, 7 (1) : 1 - 18
  • [10] Is inadequate risk stratification diluting hazard ratio estimates in randomized clinical trials?
    Mehrotra, Devan, V
    West, Rachel Marceau
    CLINICAL TRIALS, 2024, 21 (05) : 571 - 575
12345